DLH Awarded DHA OMNIBUS IV Military Medical Research and Development Contract
May 25 2022 - 8:00AM
DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the
“Company”), a leading provider of innovative healthcare
services and solutions to federal agencies, today announced that it
has been awarded an Indefinite Delivery/Indefinite Quantity (ID/IQ)
multiple award contract to provide health-related research and
development and support services to the Department of Defense
(“DoD”).
DLH will compete for individual task orders
across two of OMNIBUS IV’s market segments – Research &
Development and Research & Development Support Services. The
contract covers medical simulation technology, research into
infectious diseases and radiation effects, battlefield healthcare,
clinical medicine, chemical and biological readiness, genomics and
omics-based research, and science technologies. The multiple-award
contract has a five-year base period and a five-year extension
option, and, in aggregate, has a $10 billion ceiling for all
awardees. Specific values will be allocated to contractors as task
orders are competed and awarded.
“DLH is committed to providing the highest
quality care to the American warfighter,” said Jackie Everett, DLH
Chief Growth Officer. “The medical research activities covered in
this contract perfectly align with our expanded core competencies –
including digital transformation, modeling and simulation,
clinical, medical, and scientific research, artificial intelligence
and machine learning, telehealth research and application, and more
– positioning us well to win task orders on this ID/IQ
contract.”
“With this vehicle DLH is in a position to help
enhance the force health readiness posture of our military through
application of our expertise across the full continuum of care –
ranging from scientific research and clinical trials through
advanced development to care delivery systems in the battlefield,”
added Zach Parker, DLH President and CEO.
About DLHDLH (NASDAQ:DLHC)
delivers improved health and readiness solutions for federal
programs through research, systems development, and innovative care
processes. The Company’s experts in public health, performance
evaluation, and health operations solve the complex problems faced
by civilian and military customers alike, leveraging digital
transformation, artificial intelligence, advanced analytics,
cloud-based applications, telehealth systems, and more. With over
2,400 employees dedicated to the idea that “Your Mission is Our
Passion,” DLH brings a unique combination of government sector
experience, proven methodology, and unwavering commitment to public
health to improve the lives of millions. For more information,
visit www.DLHcorp.com.
Safe Harbor Statement under the Private
Securities Litigation Reform Act of 1995:This press
release may contain forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. These
statements relate to future events or DLH’s future financial
performance. Any statements that refer to expectations, projections
or other characterizations of future events or circumstances or
that are not statements of historical fact (including without
limitation statements to the effect that the Company or its
management “believes”, “expects”, “anticipates”, “plans”, “intends”
and similar expressions) should be considered forward looking
statements that involve risks and uncertainties which could cause
actual events or DLH’s actual results to differ materially from
those indicated by the forward-looking statements. Forward-looking
statements in this release include, among others, statements
regarding estimates of future revenues, operating income, earnings
and cash flow. These statements reflect our belief and assumptions
as to future events that may not prove to be accurate. Our actual
results may differ materially from such forward-looking statements
made in this release due to a variety of factors, including: the
outbreak of the novel coronavirus (“COVID-19”), including the
measures to reduce its spread, and its impact on the economy and
demand for our services, are uncertain, cannot be predicted, and
may precipitate or exacerbate other risks and uncertainties; the
risk that we will not realize the anticipated benefits of
acquisitions; the challenges of managing larger and more widespread
operations; contract awards in connection with re-competes for
present business and/or competition for new business; compliance
with new bank financial and other covenants; changes in client
budgetary priorities; government contract procurement (such as bid
and award protests, small business set asides, loss of work due to
organizational conflicts of interest, etc.) and termination risks;
the ability to successfully integrate the operations of
acquisitions; the impact of inflation and higher interest rates;
and other risks described in our SEC filings. For a discussion of
such risks and uncertainties which could cause actual results to
differ from those contained in the forward-looking statements, see
“Risk Factors” in the Company’s periodic reports filed with the
SEC, including our Annual Report on Form 10-K for the fiscal year
ended September 30, 2021, as well as subsequent reports filed
thereafter. The forward-looking statements contained herein are not
historical facts, but rather are based on current expectations,
estimates, assumptions and projections about our industry and
business.
Such forward-looking statements are made as of
the date hereof and may become outdated over time. The Company does
not assume any responsibility for updating forward-looking
statements, except as may be required by law.
INVESTOR RELATIONSContact:
Chris WittyPhone: 646-438-9385Email: cwitty@darrowir.com
DLH (NASDAQ:DLHC)
Historical Stock Chart
From Aug 2024 to Sep 2024
DLH (NASDAQ:DLHC)
Historical Stock Chart
From Sep 2023 to Sep 2024